20 November 2019
Moscow, November 20, 2019 – Russian pharmaceutical company NovaMedica announces the appointment of Marina Egorova, formerly director of business development, as head of the company’s commercial unit. Yulia Sobakina, who was in charge of commerce and marketing at NovaMedica since November 2017, will move on to assume the position of commercial director at Magnit Pharma LLC.
“We greatly appreciate Yulia Sobakina’s significant contribution to the development of our company’s commercial and hospital business, and wish her every success in her future work and an outstanding career”, says Elena Litvinova, CEO of NovaMedica. “NovaMedica’s plans in distribution and promotion of new products are very ambitious, and there are important and interesting challenges awaiting the new head of commerce. We are glad to have at this key position a candidate from within, who will maintain continuity in dealing with business objectives”.
Marina Egorova relies on more than 20 years of experience in the pharmaceutical industry. Prior to joining the NovaMedica team in 2017, she was the national sales manager for Russia at the international company Galderma. Before that, Marina held executive positions in sales and marketing units of Unipharm and Akrikhin, and was the region director at Boehringer Ingelheim and regional director for marketing at the leading pharmaceutical distributor Protek.
Marina Egorova graduated from the Nizhny Novgorod Commercial Institute of the Lobachevsky Nizhny Novgorod State University with a degree in Economics and Banking and from the Open University Business School of the Moscow Institute of Management LINK with a degree in Management and Project Leadership.
About the company:
NovaMedica is a modern Russian pharmaceutical company founded in 2012 by RUSNANO JSC and the US venture capital fund Domain Associates LLC. NovaMedica's strategy is aimed at search, registration and localization in Russia of intellectual property rights for innovative pharmaceutical products and technologies, as well as at development and implementation of own R&D projects and creation of a modern GMP manufacturing facility. NovaMedica has a well-developed infrastructure for promotion and sales of pharmaceutical products. In 2017, the company launched in Moscow its own R&D center NovaMedica Innotech, which has state-of-the-art technological capabilities that were previously unavailable in the Russian pharmaceutical industry. NovaMedica is also building a modern facility in the Kaluga region for production of sterile injectables. In March 2018, NovaMedica, the Russian Ministry of Industry and Trade and the Kaluga region signed the Special Investment Contract (SPIC) for the creation of this new pharmaceutical manufacturing site.
Contacts for mass media: Tatiana Albaut , +79175451241
04 March 2021
04 March 2021
03 March 2021
03 March 2021